Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2021

View Archived Issues

JDQ-443: a mutant-selective, irreversible inhibitor of KRAS G12C with an unprecedented binding mode

miR-7-5p and miR-375-3p: new circulating markers of pituitary NETs

2,3-Disubstituted pyridine IDO1 inhibitors with improved drug-like properties

Thymic stromal lymphopoietin and T cells shown to homeostatically regulate sebum production

Study identifies cell state as oncogene enabler

AMMS patents carbonic anhydrase inhibitors

Bristol Myers Squibb presents PADI4 inhibitors

Haim Bio synthesizes new antiepileptics

Stingray Therapeutics presents new ENPP1 inhibitors

AstraZeneca discloses adenosine receptor antagonists

Variants in PI4KA linked to severe neurometabolic disorder

New kratom derivatives identified with mu-opioid receptor modulatory activity

Deficient H2A.Z deposition tied to uterine leiomyoma

Celsion reports in vivo data on PLACCINE DNA vaccine platform against SARS-CoV-2

QGC-606 prevents LV dysfunction in mice post-MI

LEO Pharma's novel IL-17A/IL-17AR interaction modulator for the oral treatment of psoriasis

New FPR2 agonists target inflammation in Alzheimer's disease

Discovery and preclinical characterization of novel cyclic dinucleotide STING agonists

SymBio collaborates with NCCS to explore use of brincidofovir in EBV-positive lymphoma

SBIR grant supports Felix Biotechnology's work on engineering bacteriophage

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...